Navigation Links
Hormone treatment helps obese people slim down

Treatment with leptin, a natural hormone that helps control body weight, could help many overweight people slim down. Discovered in 1994, leptin is normally produced by fat cells and is believed to provide a signal about the amount of body fat to the body's energy-regulation system. //

Leptin treatment has already helped people who completely lack the hormone because of a genetic mutation. But only a handful of people don't have any leptin at all naturally. Results of treatment with other obese people have been disappointing, with only some subjects losing small amounts of weight.

The work suggests that leptin treatment can help not only those very rare overweight people who completely lack the hormone, but also those with low levels. There may be some unknown problems with their leptin genes or their body's ability to produce leptin. Individuals with such problems might be predisposed to become obese and might benefit from leptin therapy.


'"/>




Page: 1

Related medicine news :

1. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
2. Hormone replacement Therapy a headache
3. Ovarian cancer in relationship with Hormone therapy
4. Hormone contraceptives lead to bone problems
5. Hormone Deficiency Results In Miscarriage
6. Hormones Linked To Migraines
7. Hormone replacement therapy helps women
8. Decrease of Hunger Hormone after Obesity Surgery
9. Possible benefits of Hormone Replacement Therapy
10. Hormone replacement therapy improves sexual function
11. Hormone therapy provides no heart benefit
Post Your Comments:
(Date:7/25/2008)... Though the number of jobs created...al companies reported a different kind of slowdown...ous months. , Seattle, WA...s created in the medical field slowed in June over... kind of slowdown that will be music to the ears o...
(Date:7/25/2008)...cKesson Corporation Executive, Robert J. Reilly, J.../ -- Aethon Inc.,( http://www.aethon.com ), the le...pply chain logistics, today announced that Robert ...esident -- Chief Financial Officer., Reilly, who ...r for,McKesson Corporation,s Specialty Pharmacy Di...
(Date:7/25/2008)...ds fluid back-up in esophagus can cause immune sys...ay News) -- The first evidence linking gastroesoph...scovered by Duke University Medical Center researc...ns was first noted in the 1970s, and since then st...rcent of asthma patients also experience GERD symp...
(Date:7/25/2008)... The Drug Information Association ...ill host the Critical Path Initiative (CPI) on the...16; Bethesda, MD) and the Critical Path Transporte... Horsham, PA (PRWEB) July 25...mation Association (DIA)] and the Food and Drug Ad...
Breaking Medicine News(10 mins):Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:People With GERD More Likely to Develop Asthma 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 3
...gy segment, pharma major Dr Reddys Laboratories Lt...ailable// in extended release tablets of 10 mg dos...he brand name 'Alfoo' is indicated for treatment o...ing men known as Benign Prostatic Hyperplasia (BPH...
...overed a method to cease the blood supply to cance... cancer//. This, if proved conclusively, will infu...ng to the scientists, a protein, discovered while ...pable of stopping the blood supply to tumors, thus...
...tropolis Health Services (India) plans to make Dub...dle East//. In a joint venture with United Arab Em... Metropolis is set to begin formal operations of i...i in August, though the soft launch took place las...
...ter when investigating for an alternative menopaus...ated hot flashes as good as estrogen. Gabapentin,...the flow of calcium in and out of the cells, which...ature. flow risks like was researchers, who have ...
Other Medicine News:Health News:Metropolis Health Plans Middle East hub in Dubai 2Health News:Gabapentin Reduced Menopausal Symptoms as Estrogen – Study Find 2
(Date:7/24/2008)...EW, Calif., July 24 /- Alex...d today that it has initiated,its second Phase 3 c...AZ-004 is an inhalation product candidate being de...tients with schizophrenia or bipolar disorder.,Ale...pid pharmacokinetic,(PK) properties resulting from...
(Date:7/24/2008)...uly 24 /- MacroChem Corpora...sults of a Phase 2 clinical trial,involving 37 pat...open-label efficacy and safety study of EcoNail, a...nychomycosis (nail fungus). The composite,primary ... defined as,negative mycology (negative fungal cul...
(Date:7/23/2008)... July 23 /PRNewswire-USNewswire/ -- The following ...Chairman Conyers, Ranking Member Smith, and Member...to testify today., Since I appeared before this C... better acquainted with the talented and dedicated...the work they do, and I have come to,appreciate th...
(Date:7/23/2008)...used on IND-Enabling Work with Protein Therapeutic...omplement System, CAMBRIDGE, Mass., July 23 /PRNe...ed it has initiated a corporate growth plan with t...executive officer and the,establishment of its hea...s,Woodruff Emlen, M.D., a co-founder of the compan...
Breaking Medicine Technology:Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 3MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 5Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Brown named Center of Excellence in Geriatric Medicine and Training 8968 1Brown named Center of Excellence in Geriatric Medicine and Training 8968 2Brown named Center of Excellence in Geriatric Medicine and Training 8968 3American College of Physicians receives grant to study cost of patient centered medical home 8965 1American College of Physicians receives grant to study cost of patient centered medical home 8965 2New discovery could reduce the health risk of high fat foods 1754 1Resilience concepts poised to aid management of coastal marine ecosystems 1751 1Resilience concepts poised to aid management of coastal marine ecosystems 1751 2
...Newswire-FirstCall/ -- Rigel Pharmaceuticals, Inc....s currently in ongoing,Phase 2 clinical trials in ...arthritis (RA) and lymphoma patients. R788 is a no...ivation of mast cells,macrophages and B-cells tha...sue damage. , Rigel commenced an exploratory Phase...
...ce in Barcelona,Spain, VANCOUVER and SAN DIEGO, C... Inc. , a clinical-stage developer,of drugs for in...ts,confirming the previously announced clinical re...inical benefit, safety and,tolerability in a Phase...or, celgosivir (MX-3253), in combination with pegy...
Other Medicine Technology:Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,Rheumatoid Arthritis and Lymphoma 2Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,Rheumatoid Arthritis and Lymphoma 3Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,Rheumatoid Arthritis and Lymphoma 4New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 2New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 3New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 4New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 5New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 6New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 7New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 8